학술논문
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFRT790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Document Type
Article
Author
Cho, Byoung Chul; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Shim, Byoung Yong; Kim, Jin-Soo; Chun, Sang Hoon; Lee, Sung Sook; Kim, Hye Ryun; Hong, Min Hee; Ahn, Jin Seok; Sun, Jong-Mu; Lee, Youngjoo; Lee, Dae Ho; Kang, Ji Ah; Lee, NaMi; Kwon, Mi-Jung; Espenschied, Carin; Yablonovitch, Arielle; Ahn, Myung-Ju
Source
Journal of Thoracic Oncology; 20220101, Issue: Preprints
Subject
Language
ISSN
15560864; 15561380
Abstract
This integrated analysis of a phase 1/2 study (NCT03046992) evaluated the efficacy and safety of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced EGFRT790M-positive NSCLC after previous EGFR TKI therapy.